Evidence map›Paper›PMID 42112146›Full record

ArticleClinical and experimental gastroenterology2026

Aimed at Subtype Discrimination but Yielding a Shared Marker: Integrative Analysis of Blood Transcriptomes Reveals Upregulated

Arman Mokaram Doust Delkhah

Abstract read
In one paragraph

Article in Clinical and experimental gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Arman Mokaram Doust DelkhahDepartment of Genetics, Mashhad, Iran.ORCID 0000-0001-6373-7999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the similarities, Crohn's disease (CD) and ulcerative colitis (UC), the two major subtypes of inflammatory bowel disease (IBD), exhibit distinctions. The increasing burden of IBD necessitates discovering novel diagnostic markers. Considering the importance of distinguishing between CD and UC in selecting therapeutic strategies in clinical settings, this investigation focused on identifying subtype-specific blood biomarkers. Methods: The discovery set was formed by integrating five blood transcriptomic datasets, including GSE119600, GSE126124, GSE94648, GSE86434, and GSE71730, which incorporated samples from CD, UC, and controls. After determining DEGs in CD and UC, they were separately filtered according to WGCNA and then analyzed by LASSO and RF algorithms. Eventually, ROC analysis of the diagnostic performances was conducted independently in the datasets used for discovery. Moreover, ROC analysis was implemented in independent cohorts to assess the generalizability of findings. Results: Initially, the identified subtype-specific candidate biomarkers included Conclusion: This integrative analysis of blood transcriptomes diverged from its initial purpose, the identification of subtype-specific biomarkers, and demonstrated that

Indexed as

biomarkersbloodIBDTLR5

Identifiers

PMID42112146
PMCPMC13155245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.